Glenmede Trust Co. NA Purchases Shares of 4,924 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Glenmede Trust Co. NA purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, according to its most recent filing with the SEC. The fund purchased 4,924 shares of the medical equipment provider’s stock, valued at approximately $540,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Signaturefd LLC increased its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its holdings in Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares during the last quarter. UMB Bank n.a. increased its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. GAMMA Investing LLC increased its holdings in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Lantheus by 4.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock valued at $533,000 after acquiring an additional 287 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on LNTH. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $125.71.

Lantheus Stock Down 1.2 %

Shares of Lantheus stock opened at $88.51 on Wednesday. The stock’s fifty day moving average is $100.44 and its two-hundred day moving average is $97.49. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a market capitalization of $6.15 billion, a PE ratio of 14.73 and a beta of 0.45.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.